Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Cited by (1,000)

Items 601–700 of 1,000

1. SEOM SOGUG clinical guideline for treatment of kidney cancer (2022)
   María José Méndez, Martín Lázaro Quintela, Nuria Laínez Milagro, Begoña Pérez‐Valderrama, Cristina Suárez, Jóse Ángel Arranz Arija, Ignacio Peláez Fernández, Enrique Gallardo, Julio Lambea Sorrosal, Aranzazu González del Alba · 2023 · Clinical & Translational Oncology
2. Recent Advances in Single-Cell RNA-Sequencing of Primary and Metastatic Clear Cell Renal Cell Carcinoma
   Adele M. Alchahin, Ιωάννα Τσέα, Ninib Baryawno · 2023 · Cancers
3. Efficacy of avelumab plus axitinib versus sunitinib by numbers of IMDC risk factors and target tumor sites at baseline in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101
   Yoshihiko Tomita, Robert John Motzer, Toni K. Choueiri, Brian I. Rini, Hideaki Miyake, Mototsugu Oya, Laurence K. Albiges, M. Aizawa, Yoshiko Umeyama, J. Wang et al. · 2023 · ESMO Open
4. Endocrine toxicity of immune checkpoint inhibitors: a network meta-analysis of the current evidence
   Peipei Ouyang, Weiting Yang, Jianqiao Sun, Ping Chen, Qingyun He, Jiaxin Yan, Wenhao Wang, Yi Wang, Heran Li, Qiuhua Luo · 2024 · Acta Materia Medica
5. Active Surveillance in Metastatic Renal Cell Carcinoma
   Nicholas J. Beecroft, Timothy D. Gauntner, Rituraj Upadhyay, Shang-Jui Wang, Yuanquan Yang, Eric A. Singer, Shawn Dason · 2024 · Journal of Kidney Cancer and VHL
6. Pathological Response and Outcomes in Patients With Metastatic Renal Cell Carcinoma (mRCC) Receiving Immunotherapy-Based Therapies and Undergoing Deferred Cytoreductive Nephrectomy (CN)
   Damla Günenç, Wadih Issa, Thomas Gerald, Qinhan Zhou, Song Zhang, Chidera Ibezue, Raj Ramnik Bhanvadia, Isamu Tachibana, James Brugarolas, Hans J. Hammers et al. · 2024 · Clinical Genitourinary Cancer
7. Understanding resistance to immune checkpoint inhibitors in advanced breast cancer
   Paolo Tarantino, Romualdo Barroso‐Sousa, Ana Christina Garrido-Castro, Sandra S. McAllister, Jennifer L. Guerriero, Elizabeth Ann Mittendorf, Giuseppe Curigliano, Sara M. Tolaney · 2021 · Expert Review of Anticancer Therapy
8. A Cost-effectiveness Analysis Comparing Pembrolizumab-Axitinib, Nivolumab-Ipilimumab, and Sunitinib for Treatment of Advanced Renal Cell Carcinoma
   Alan Chan, Carolyn Dang, Jessica Wisniewski, Xiuhua Weng, Edward Hynson, Lixian Zhong, Leslie Wilson · 2022 · American Journal of Clinical Oncology
9. Significance of upfront cytoreductive nephrectomy stratified by IMDC risk for metastatic renal cell carcinoma in targeted therapy era – a multi-institutional retrospective study
   Renpei Kato, Sei Naito, Kazuyuki Numakura, Shingo Hatakeyama, Tomoyuki Koguchi, Takahiro Kojima, Yoshihide Kawasaki, Shuya Kandori, Sadafumi Kawamura, Yoichi Arai et al. · 2022 · International Journal of Clinical Oncology
10. Exploring the synergistic effects of cabozantinib and a programmed cell death protein 1 inhibitor in metastatic renal cell carcinoma with machine learning
    Ignacio Durán, Daniel Castellano, Javier Puente, Lidia Martín-Couce, Esther Bello, Urbano Anido, José Manuel Mas, Luís Costa · 2022 · Oncotarget
11. Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison
    Matteo Santoni, Gaetano Aurilio, Francesco Massari, Enrique Grande, Marc Ryan Matrana, Mimma Rizzo, Ugo De Giorgi, Lorena Incorvaia, Angelo Martignetti, Javier Molina‐Cerrillo et al. · 2022 · Clinical Genitourinary Cancer
12. An autologous humanized patient-derived xenograft (PDX) model for evaluation of nivolumab immunotherapy in renal cell cancer: a case report
    Yubin Kang, Andrew J. Armstrong, David S. Hsu · 2022 · Stem Cell Investigation
13. Associating Immunotherapy and Targeted Therapies: Facts and Hopes
    Sylvain Ladoire, Cédric Rébé, François Ghiringhelli · 2022 · Clinical Cancer Research
14. Therapeutic Management of Metastatic Clear Cell Renal Cell Carcinoma: A Revolution in Every Decade
    Mathieu Larroquette, Félix Lefort, Luc Héraudet, Jean‐Christophe Bernhard, Alain Ravaud, Charlotte Domblides, Marine Gross‐Goupil · 2022 · Cancers
15. Perspectives in Immunotherapy: meeting report from Immunotherapy Bridge (Naples, November 30th–December 1st, 2022)
    Paolo A. Ascierto, Antonio Avallone, Carlo Bruno Bifulco, Sergio Bracarda A, Joshua Brody, Leisha A. Emens, Robert Louis Ferris, Silvia Chiara Formenti, Omid Hamid, Douglas Buckner Johnson et al. · 2023 · Journal of Translational Medicine
16. Endogenous Pancreatic Cancer Cell PD-1 Activates MET and Induces Epithelial-Mesenchymal Transition to Promote Cancer Progression
    Megan M. Harper, Miranda Lin, Shadi A. Qasem, Reema Anil Patel, Michael J. Cavnar, Prakash Krishnan Pandalai, Mei Gao, Joseph Kim · 2022 · Cancers
17. Cancer Cell-Derived PDGFB Stimulates mTORC1 Activation in Renal Carcinoma
    Asmaa Y. Abuhamad, Nurul Nadia Mohamad Zamberi, Sakari Vanharanta, Siti Nur Hasanah Mohd Yusuf, M. Aiman Mohtar, Saiful Effendi Syafruddin · 2023 · International Journal of Molecular Sciences
18. Adverse events of PD-(L)1 inhibitors plus anti-VEGF(R) agents compared with PD-(L)1 inhibitors alone for cancer patients: a systematic review and meta-analysis
    Qiyu Tang, Dawei Wu, Huiyao Huang, Hong Fang, Ying Wu, Funan Liu, Ning Li · 2023 · Frontiers in Pharmacology
19. Critical review of the current and future prospects of VEGF-TKIs in the management of squamous cell carcinoma of head and neck
    Prashant Puttagunta, Saagar V. Pamulapati, James E. Bates, Jennifer H. Gross, William A. Stokes, Nicole Cherie Schmitt, Conor Ernst Steuer, Yong Teng, Nabil F. Saba · 2023 · Frontiers in Oncology
20. The Novel HDAC Inhibitor OBP-801 Promotes MHC Class I Presentation Through LMP2 Upregulation, Enhancing the PD-1-Targeting Therapy in Clear Cell Renal Cell Carcinoma
    Tsukasa Narukawa, Shusuke Yasuda, Mano Horinaka, Keiko Taniguchi, Takahiro Tsujikawa, Mie Morita, Osamu Ukimura, Toshiyuki Sakai · 2024 · Cancers
21. Prevailing challenges in personalized treatment for metastatic renal cell carcinoma: a narrative review
    Ryosuke Oki, Kosuke null Takemura, Tetsuya Urasaki, Ryo Fujiwara, Noboru Numao, Junji Yonese, Yuji Miura, Takeshi Yuasa · 2025 · Expert Review of Anticancer Therapy
22. The Effectiveness and Safety Profile of Nivolumab‐Plus‐Ipilimumab in Previously Untreated Japanese Patients With Advanced or Metastatic Renal Cell Carcinoma (J‐ ENCORE Study)
    Koshiro Nishimoto, Go Kimura, Tomokazu Sazuka, Shuzo Hamamoto, Masahiro Nozawa, Kazuyuki Numakura, Atsushi Mizokami, Tsunenori Kondo, Sei Naito, Takashige Abe et al. · 2025 · International Journal of Urology
23. Angiogenic and immune predictors of neoadjuvant axitinib response in renal cell carcinoma with venous tumour thrombus
    Rebecca Wray, Hania Paverd, Ines Prata Machado, Johanna Barbieri, Farhana Easita, Abigail R. Edwards, Ferdia Aidan Gallagher, Iosif Alexandru Mendichovszky, Thomas J. Mitchell, Maike de la Roche et al. · 2025 · Nature Communications
24. Comparison of real-world outcomes between nivolumab plus ipilimumab and lenvatinib plus pembrolizumab or nivolumab plus cabozantinib combination therapies for previously untreated advanced renal cell carcinoma
    Hiroki Ishihara, Kenji Omae, Yuki Nemoto, Shinsuke Mizoguchi, Nanaka Katsurayama, Takayuki Nakayama, Hironori Fukuda, Kazuhiko Yoshida, Hiroaki Shimmura, Yasunobu Hashimoto et al. · 2025 · Urologic Oncology Seminars and Original Investigations
25. Regulatory T cells in renal cell carcinoma: tumor-promoting mechanisms and emerging therapeutic strategies
    Zuolei Li, Jing Ma, Mengdie Xu, Yi Duan, Conggai Huang, Qiong Dai, Zhihui Yang · 2025 · International Immunopharmacology
26. Sintilimab Plus Axitinib for Advanced Fumarate Hydratase–Deficient Renal Cell Carcinoma
    Xingming Zhang, Haoyang Liu, Jiayu Liang, Junjie Zhao, Yongquan Wang, Yuntian Chen, Deying Kang, Qian Chen, Yaowen Zhang, Xiaoxue Yin et al. · 2025 · JAMA Oncology
27. AI-driven multimodal algorithm predicts immunotherapy and targeted therapy outcomes in clear cell renal cell carcinoma
    Danil Stupichev, Natalia Miheecheva, Ekaterina Postovalova, Yang Lyu, Akshaya Ramachandran, Ilya Galkin, Gleb Khegai, Kristina Perevoshchikova, Anna Love, Sofia Menshikova et al. · 2025 · Cell Reports Medicine
28. Real-world outcomes of immune checkpoint inhibitor-based combination therapy in older adult patients with metastatic renal cell carcinoma: a multi-center, retrospective analysis
    Hiroaki Ikoma, Shuzo Hamamoto, Yoshihiko Tasaki, Misato Tomita, Takuya Sakata, Hiroko Suzuki, Yusuke Noda, Masayuki Usami, Yohei Tsubouchi, Yoshihisa Mimura et al. · 2025 · Frontiers in Immunology
29. Tumor microenvironment-driven drug resistance in urologic cancers: mechanisms and therapeutic targets
    Gi‐Eun Yang, Seo‐Yeong Yoon, Ju‐Seog Lee, Sun‐Hee Leem, Yung Hyun Choi · 2025 · Genes & Genomics
30. Cost-Effectiveness of Nivolumab Plus Cabozantinib Versus Sunitinib as a First-Line Treatment for Advanced Renal Cell Carcinoma in the United States
    Sini Li, Jianhe Li, Liubao Peng, Yamin Li, Xiaomin Wan · 2021 · Frontiers in Pharmacology
31. Primary Tumor Shrinkage and the Effect on Metastatic Disease and Outcomes in Patients With Advanced Kidney Cancer With Intermediate or Poor Prognosis Treated With Nivolumab Plus Ipilimumab or Cabozantinib
    Roberto Iacovelli, Chiara Ciccarese, Marco Maruzzo, Francesco Atzori, Luca Galli, Sarah Scagliarini, Francesco Massari, Elena Verzoni, Antonella Cannella, Maria Grazia Maratta et al. · 2022 · Clinical Genitourinary Cancer
32. A Systematic Review of Immune Checkpoint Inhibitors in Non-Clear-Cell Renal Cancer
    Ana Filipa Palma dos Reis, Diana Cardoso Simão, Thomas Odeny, Chiara Rodrigues, Mário Fontes-Sousa, Ricardo da Luz, Rajasree Pia Chowdry, Sarah Joanne Welsh, Channing Judith Paller, Pedro Coelho Barata · 2022 · Kidney Cancer
33. Immunotherapy in advanced kidney cancer: an alternative meta-analytic method using reconstructed survival data in case of proportional hazard assumption violation
    Luigi Nocera, Giuseppe Fallara, Daniele Raggi, Federico Belladelli, Daniele Robesti, Francesco Montorsi, Pierre I. Karakiewicz, Bernard A. Malavaud, Guillaume Ploussard, Andrea Necchi et al. · 2022 · Frontiers in Oncology
34. Optimization of first‐line systemic therapy in patients with advanced clear cell renal cell carcinoma
    Toshio Takagi · 2022 · International Journal of Urology
35. Outcomes With Combination Pembrolizumab and Axitinib in Second and Further Line Treatment of Metastatic Renal Cell Carcinoma
    Nazlı Dizman, Matthew Austin, Bryden Considine, Shlomit Jessel, David A. Schoenfeld, Man Yee Merl, Michael E. Hurwitz, Mario Sznol, Harriet M. Kluger · 2023 · Clinical Genitourinary Cancer
36. A group of novel VEGF splice variants as alternative therapeutic targets in renal cell carcinoma
    Christopher Montemagno, Jérôme Durivault, Cécile Gastaldi, Maeva Dufies, Valérie Vial, Xingkang He, Damien Ambrosetti, Anna Kamenskaya, Sylvie Négrier, Jean‐Christophe Bernhard et al. · 2023 · Molecular Oncology
37. Immune checkpoint inhibitors combined with tyrosine kinase inhibitors or immunotherapy for treatment-naïve metastatic clear-cell renal cell carcinoma—A network meta-analysis. Focus on cabozantinib combined with nivolumab
    Maciej Niewada, Tomasz Macioch, Magdalena Konarska, Aneta Mela, Adam Goszczyński, Bogusława Przekopińska, Karolina Rajkiewicz, Piotr Jan Wysocki, Maciej Jerzy Krzakowski · 2023 · Frontiers in Pharmacology
38. Survival in Metastatic Renal Cell Carcinoma Treated With Immunotherapy and Stereotactic Radiation Therapy or Immunotherapy Alone: A National Cancer Database Analysis
    Alexander Piening, Noor J. Al-Hammadi, John J. Dombrowski, Zachary Adam Hamilton, Ryan M. Teague, Anand Swaminath, Jeevin Shahi · 2023 · Advances in Radiation Oncology
39. A phase II study of alternating sunitinib and temsirolimus therapy in patients with metastatic renal cell carcinoma
    Dylan B. Ness, Darcy B. Pooler, Steven Ades, Brian J. Highhouse, Bridget M. Labrie, Jie Zhou, Jiang Gui, Lionel D. Lewis, Marc S. Ernstoff · 2023 · Cancer Medicine
40. Triplet Strategies in Metastatic Clear Cell Renal Cell Carcinoma: A Worthy Option in the First-Line Setting?
    Catherine C. Fahey, Jeffrey W. Shevach, Ronan Flippot, Laurence K. Albiges, Naomi Balzer Haas, Kathryn Eby Beckermann · 2023 · American Society of Clinical Oncology Educational Book
41. Identification of a novel combination treatment strategy in clear cell renal cell carcinoma stem cells with shikonin and ipilimumab
    Chen Lyu, Birgit Stadlbauer, Lili Wang, Alexander Büchner, Heike Pohla · 2023 · Frontiers in Immunology
42. Real world treatment sequences and outcomes for metastatic renal cell carcinoma
    Gu-Shun Lai, Jian‐Ri Li, Shian‐Shiang Wang, Chuan-Shu Chen, Chun‐Kuang Yang, Chia‐Yen Lin, Sheng-Chun Hung, Kun‐Yuan Chiu, Shun‐Fa Yang · 2023 · PLoS ONE
43. Real‐world outcomes of avelumab plus axitinib as first‐line therapy in patients with advanced renal cell carcinoma in Japan: A multicenter, retrospective, observational study (J‐DART)
    Taigo Kato, Yuzo Nakano, Fumiya Hongo, Hidenori Katano, Tomoaki Miyagawa, Kousuke Ueda, Haruhito Azuma, Masahiro Nozawa, Nobuyuki Hinata, Junichi Hori et al. · 2023 · International Journal of Urology
44. Predictive factors of nivolumab plus ipilimumab treatment efficacy in metastatic renal cell carcinoma patients
    Kojiro Ohba, Hiromi Nakanishi, Ken Kawada, Yuichiro Nakamura, Kensuke Mitsunari, Tomohiro Matsuo, Yasushi Mochizuki, Ryoichi Imamura · 2024 · Japanese Journal of Clinical Oncology
45. A phase II study of cabozantinib and pembrolizumab in advanced gastric/gastroesophageal adenocarcinomas resistant or refractory to immune checkpoint inhibitors
    Farshid Dayyani, Joseph Chao, Fa-Chyi Lee, Thomas H. Taylor, Kristen Neumann, May Thet Cho · 2024 · The Oncologist
46. Combined use of tyrosine kinase inhibitors with PD-(L)1 blockade increased the risk of thyroid dysfunction in PD-(L)1 blockade: a prospective study
    Tomoko Kobayashi, Shintaro Iwama, Ayana Yamagami, Tetsushi Izuchi, Koji A. O. Suzuki, Koki Otake, Yoshinori Yasuda, Masahiko Ando, Takeshi Onoue, Takashi Miyata et al. · 2024 · Cancer Immunology Immunotherapy
47. STELLAR-303: randomized phase III study of zanzalintinib + atezolizumab in previously treated metastatic colorectal cancer
    Anwaar Saeed, Josep M. Tabernero, Aparna R. Parikh, Marc Van den Eynde, Meinolf Karthaus, Marco Gerlinger, Zhong Wang, Guan Wang, Robina Smith, Joel Randolph Hecht · 2024 · Future Oncology
48. Impact of Timing of Immunotherapy and Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: Real-World Data on Survival Outcomes from the CKCis Database
    Changsu L Park, Feras Ayman Moria, Sunita Ghosh, Lori Anne Wood, Georg A. Bjarnason, Bimal Bhindi, Daniel Yick Chin Heng, Vincent Castonguay, Frédéric Pouliot, Christian Kollmannsberger et al. · 2024 · Current Oncology
49. Albumin-to-Alkaline Phosphatase Ratio as a Novel Prognostic Marker of Nivolumab Monotherapy for Previously Treated Metastatic Renal Cell Carcinoma
    Maki Yoshino, Hiroki Ishihara, Yudai Ishiyama, Hidekazu Tachibana, Daisuke Toki, Kaori Yamashita, Hirohito Kobayashi, Hironori Fukuda, Kazuhiko Yoshida, Toshio Takagi et al. · 2021 · In Vivo
50. Nivolumab Reduces PD1 Expression and Alters Density and Proliferation of Tumor Infiltrating Immune Cells in a Tissue Slice Culture Model of Renal Cell Carcinoma
    Philipp Stenzel, Nina Hörner, Sebastian Foersch, Daniel‐Christoph Wagner, Igor Tsaur, Anita Thomas, Axel Haferkamp, Stephan Macher‐Goeppinger, Wilfried Roth, Štefan Porubský et al. · 2021 · Cancers
51. Use of Second-line Immunotherapy in Control Arms of Randomized Clinical Trials in Kidney Cancer
    John Sharp, Ali Raza Khaki, Vinay K. Prasad · 2021 · JAMA Network Open
52. Outcomes following cytoreductive nephrectomy without immediate postoperative systemic therapy for patients with synchronous metastatic renal cell carcinoma
    Jack R. Andrews, Christine Marie Lohse, Stephen Anthony Boorjian, Bradley C. Leibovich, Houston R. Thompson, Brian Addis Costello, Bimal Bhindi · 2022 · Urologic Oncology Seminars and Original Investigations
53. Front-Line Therapy for Metastatic Renal Cell Carcinoma: A Perspective on the Current Algorithm and Future Directions
    Ameish Govindarajan, Daniela V. Castro, Zeynep Büşra Zengin, Sabrina K. Salgia, Jalen Patel, Sumanta Kumar Pal · 2022 · Cancers
54. Changes in Real-World Outcomes in Patients with Metastatic Renal Cell Carcinoma from the Molecular-Targeted Therapy Era to the Immune Checkpoint Inhibitor Era
    Hiroki Ishihara, Yuki Nemoto, Kazutaka Nakamura, Hidekazu Tachibana, Hironori Fukuda, Kazuhiko Yoshida, Hirohito Kobayashi, Junpei Iizuka, Hiroaki Shimmura, Yasunobu Hashimoto et al. · 2022 · Targeted Oncology
55. Advanced materials for management of immune-related adverse events induced by immune checkpoint inhibitors
    Lingnan Zheng, Xi Yang, Yuanfeng Wei, Jia You, Huawei Li, Jinfeng Liao, Yi Cheng · 2022 · Materials & Design
56. A novel thinking: DDR axis refines the classification of ccRCC with distinctive prognosis, multi omics landscape and management strategy
    Aimin Jiang, Jiaao Song, Xiao Fang, Yu Fang, Zheng Wang, Bing Liu, Zhenjie Wu, Le Qu, Peng Luo, Linhui Wang · 2022 · Frontiers in Public Health
57. Combining Sunitinib and Bevacizumab for the Management of Advanced Renal Cell Carcinoma: A Phase I/II Trial
    Shouki N. Bazarbashi, Ahmed Alzahrani, Ali Husain Aljubran, Mahmoud A. Elshenawy, Ahmed Gad, Fatma Maraiki, Noura Alzannan, Tusneem Ahmed M. Elhassan, Ahmed Ali Badran · 2023 · The Oncologist
58. Development of a TGF-β signaling-related genes signature to predict clinical prognosis and immunotherapy responses in clear cell renal cell carcinoma
    Xin Wu, Wenjie Xie, Binbin Gong, Bin Fu, Wei-Min Chen, Libo Zhou, Lianmin Luo · 2023 · Frontiers in Oncology
59. Hemoglobin and neutrophil levels stratified according to International Metastatic Renal Cell Carcinoma Database Consortium risk predict the effectiveness of ipilimumab plus nivolumab in patients with advanced metastatic renal cell carcinoma
    Nami Tomiyama, Yoshihiko Tasaki, Shuzo Hamamoto, Yosuke Sugiyama, Taku Naiki, Toshiki Etani, Kazumi Taguchi, Nayuka Matsuyama, Yasuhito Sue, Yoshihisa Mimura et al. · 2023 · International Journal of Urology
60. Localized PD-1 Blockade in a Mouse Model of Renal Cell Carcinoma
    Ngoc Bich Pham, Nevil Abraham, Ketki Y. Velankar, Nathan R. Schueller, Errol James Philip, Yasmeen Jaber, Ellen S. Gawalt, Yong Fan, Sumanta Kumar Pal, Wilson S. Meng · 2022 · Frontiers in Drug Delivery
61. Established and Emerging Biomarkers of Immunotherapy in Renal Cell Carcinoma
    Yash C. Jani, Caroline Stewart Jansen, Margo Brooke Gerke, Mehmet Asım Bilen · 2024 · Immunotherapy
62. Treatment options in first-line metastatic renal carcinoma: A meta-analysis of 2556 patients treated with immune checkpoint inhibitors-based combinations in randomised controlled trials
    Marcello Tucci, Marta Mandarà, Jacopo Giuliani, Emilia Durante, Consuelo Buttigliero, Fabio Turco, Erica Palesandro, Ilaria Campisi, Navdeep Singh, Marco Muraro et al. · 2024 · Cancer Treatment Reviews
63. Health Care Resource Use for Modern First-Line Treatments in Metastatic Renal Cell Carcinoma
    Neil J. Shah, Reshma Shinde, Kristin J. Moore, Amy M. Sainski-Nguyen, Lisa B. Le, Feng Cao, Rui Song, Puneet K. Singhal, Robert John Motzer · 2024 · JAMA Network Open
64. The role of cytoreductive nephrectomy in the era of immune checkpoint inhibitors: A review of current evidence and ongoing trials
    Takuto Hara, Hideaki Miyake · 2024 · International Journal of Urology
65. Sex differences in immunotherapy outcomes and tumor-infiltrating immune cell profiles in patients with advanced renal cell carcinoma
    Hiroki Ishihara, Hironori Fukuda, Yukihiro Mizoguchi, Makiko Yamashita, Kazunori Aoki, Ryo Ishiyama, Takashi Ikeda, Yuki Nemoto, Hiroaki Shimmura, Yasunobu Hashimoto et al. · 2025 · Cancer Immunology Immunotherapy
66. Immunotherapy Strategies After Immune Checkpoint Inhibitor Exposure in Renal Cell Carcinoma
    Giulia Claire Giudice, Kathryn Eby Beckermann, Paulo Siqueira Amaral, Brian I. Rini · 2025 · JAMA Oncology
67. Belzutifan's role in the treatment landscape of clear cell renal cell carcinoma
    Adrienne H. Chen, Allison K. Grana · 2025 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
68. High Circulating IL-6/IL-8 Is Associated with Intratumoral Myeloid Contexture and Poor Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade
    Lucía Carril-Ajuria, Ronan Flippot, Marie Naigeon, Cécile Dalban, Aude Desnoyer, Nathalie C. Rioux-Leclercq, Catherine Sautès‐Fridman, Maxime Meylan, Yann Alexandre Vano, Benoit Beuselinck et al. · 2025 · Clinical Cancer Research
69. Assessing the Pharmacological and Pharmacogenomic Data of PD-1/PD-L1 Inhibitors to Enhance Cancer Immunotherapy Outcomes in the Clinical Setting
    Damianos-Ioannis Zervanos, Eleftheria Galatou, Αndroulla N. Miliotou, Nikoleta F. Theodoroula, Nikolaos Grigoriadis, Ioannis S. Vizirianakis · 2025 · Future Pharmacology
70. Comparative efficacy of immune checkpoint inhibitor combination therapies by metastatic site in metastatic renal cell carcinoma
    Shingo Toyoda, Lan Inoki, Mamoru Hashimoto, Wataru Fukuokaya, Keiichiro Mori, Shingo Nishimura, Ryoichi Maenosono, Takehiro Iwata, Kensuke Bekku, Takuhisa Nukaya et al. · 2026 · Scientific Reports
71. NKG2D upregulation sensitizes tumors to combined anti-PD1 and anti-VEGF therapy and prevents hearing loss
    Simeng Lu, Zhenzhen Yin, Limeng Wu, Yao Sun, Jie Chen, Lai Man Natalie Wu, Janet L. Oblinger, Day Caven Blake, Bingyu Xiu, Lukas David Landegger et al. · 2026 · Nature Communications
72. Neoadjuvant Systemic Therapy in Localized and Locally Advanced Renal Cell Carcinoma
    Sari Safaa Khaleel, Song Jiang, Ritesh R. Kotecha, A. Ari Hakimi · 2022 · Frontiers in Urology
73. Sustained release system of paclitaxel based on composite nanofibers for inhibiting renal clear cell carcinoma
    Zhiduan Cai, Haoquan Zhuang, Xiezhao Li, Siyang Liang, Wenjun Luo, Yaoji Yuan, Yuyu Xu, Lin Jin, Guibin Xu · 2022 · Journal of Materials Science
74. Optimizing targeted drug selection in combination therapy for patients with advanced or metastatic renal cell carcinoma: A systematic review and network meta‐analysis of safety
    Ruiyang Xie, Jie Wu, Bingqing Shang, Xingang Bi, Weixing Jiang, Chuanzhen Cao, Aiping Zhou, Hongzhe Shi, Jianzhong Shou · 2022 · Cancer Medicine
75. Research Progress of Tumor Microenvironment Targeted Therapy for Clear Cell Renal Cell Carcinoma
    Yongqiang Huang, Hong Sun, Pu Guo · 2023 · Cancer Control
76. Rationale for Prostate-Specific-Membrane-Antigen-Targeted Radionuclide Theranostic Applied to Metastatic Clear Cell Renal Carcinoma
    Anne‐Laure Giraudet, Armelle Vinceneux, Valentin Pretet, Emilie Paquet, A. Sánchez Lajusticia, Fouzi Khayi, Jean‐Noël Badel, Helen J. Boyle, Aude Fléchon, David Kryza · 2023 · Pharmaceuticals
77. Comprehensive analysis of the prognosis and immune infiltration of TMC family members in renal clear cell carcinoma
    Wenbin Tang, Zhiyuan Shi, Yasheng Zhu, Zhengda Shan, Aimin Jiang, Anbang Wang, Ming Chen, Yi Bao, Guanqun Ju, Weidong Xu et al. · 2023 · Scientific Reports
78. Integrating Red Blood Cell Features and Hemoglobin Levels in Metastatic Renal Cell Carcinoma Patients Treated with Pazopanib or Cabozantinib: An Easily Exploitable Prognostic Score
    Giulia Mazzaschi, Alessandro Lazzarin, Matteo Santoni, Francesca Trentini, Ugo De Giorgi, Nicole Brighi, Chiara Tommasi, Silvia Puglisi, Orazio Caffo, Stefania Kinspergher et al. · 2023 · Frontiers in Bioscience-Elite
79. Cytoreductive nephrectomy in the age of immunotherapy-based combination treatment
    Sang Hun Song, Sangchul Lee · 2023 · Korean journal of urology
80. Outcomes of Patients With Advanced Renal Cell Carcinoma With Non-Clear Cell Histology Treated With Systemic Therapy
    Danielle S. Urman, Leah Deshler, Nicole Weise, Ahmed S. Shabaik, Ithaar Derweesh, Aditya Bagrodia, Brent Shane Rose, Daniel Herchenhorn, Rana R. McKay · 2023 · Clinical Genitourinary Cancer
81. Real-World Results of Cabozantinib Given as Alternative Schedule in Metastatic Renal Cell Carcinoma
    Andreas Bruchbacher, Johannes Franke, Arman Alimohammadi, Ekaterina Laukhtina, Harun Fajković, Manuela Schmidinger · 2023 · Clinical Genitourinary Cancer
82. Prognostic Impact of Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab: A Multicenter Retrospective Study
    Takuhisa Nukaya, Kiyoshi Takahara, Atsuhiko Yoshizawa, Masanobu Saruta, Yusuke Yano, Takaya Ohno, Taizo Uchimoto, Wataru Fukuokaya, Takahiro Adachi, Shogo Yamazaki et al. · 2023 · Clinical Genitourinary Cancer
83. Immuno-Oncology Advances in Genitourinary Cancers
    Peter D. Zang, Arkhjamil Angeles, Tanya Barauskas Dorff, Sumanta Kumar Pal, Shilpa Gupta · 2024 · American Society of Clinical Oncology Educational Book
84. Risk of cardiovascular toxicity with combination of immune-checkpoint inhibitors and angiogenesis inhibitors: a meta-analysis
    Alessandro Inno, Antonello Veccia, Giorgio Madonia, Alvise Berti, Roberto Bortolotti, Lorena Incorvaia, Antonio Dello Russo, Orazio Caffo, Stefania Gori · 2024 · Frontiers in Cardiovascular Medicine
85. Association Between Sex and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta Analysis
    Jianxiong Lai, Xiaohong Kuang, Yi Fu, Jian Li · 2024 · Immunotherapy
86. Advanced renal cell carcinoma management: the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG) consensus update
    Andrey Soares, Fernando Sabino Marques Monteiro, Karine Martins da Trindade, Adriano Gonçalves e Silva, Ana Paula Garcia Cardoso, André Deeke Sasse, André P. Fay, André Paternò Castello Dias Carneiro, Antonio Machado Alencar, Augusto César de Andrade Mota et al. · 2024 · Journal of Cancer Research and Clinical Oncology
87. Perioperative systemic treatments in renal cell carcinoma
    Rohit Vivek Goswamy, Ecem Kalemoglu, Viraj A. Master, Mehmet Asım Bilen · 2024 · Frontiers in Oncology
88. Multidisciplinary systemic and local therapies for metastatic renal cell carcinoma: a narrative review
    Martín Zarbá, Ryo Fujiwara, Takeshi Yuasa, Fumitaka Koga, Daniel Y.C. Heng, Kosuke null Takemura · 2024 · Expert Review of Anticancer Therapy
89. Real-world treatment trends for patients with advanced prostate cancer and renal cell carcinoma and their cost—a survey in Japan
    Takahiro Osawa, Keita Sasaki, Ryunosuke Machida, Takashi Matsumoto, Yoshiyuki Matsui, Hiroshi Kitamura, Hiroyuki Nishiyama · 2024 · Japanese Journal of Clinical Oncology
90. Cross‐sectional study of therapy‐related expectations/concerns of patients with metastatic renal cell carcinoma and physicians in Japan
    Go Kimura, Yasuhisa Fujii, Takahiro Osawa, Yosuke Uchitomi, Kazunori Honda, Miki Kondo, Ariko Otani, Tetsuya Wako, Daisuke Kawai, Yoshihide Mitsuda et al. · 2024 · Cancer Medicine
91. Treatment Preferences Among Patients with Renal Cell Carcinoma: Results from a Discrete Choice Experiment
    Moshe Chaim Ornstein, Lisa C. Rosenblatt, Xin Yin, Viviana Del Tejo, Sarah B. Guttenplan, Flavia Ejzykowicz, Kathleen Marie Beusterien, Oliver Will, deMauri S. Mackie, Grace Skiles et al. · 2024 · Patient Preference and Adherence
92. Focal therapy for oligometastatic and oligoprogressive renal cell carcinoma: a narrative review
    A. Anderson, Joel Ho, Evan Thomas Hall, Raquibul Hannan, Jay Justin Liao, Alexander V. Louie, Ting Martin Ma, Sarah P. Psutka, Ramesh Rengan, Shankar Siva et al. · 2024 · Future Oncology
93. Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1)
    Daniele Santini, Haoran Li, Giandomenico Roviello, Se Hoon Park, Enrique Grande, Jakub Kucharz, Umberto Basso, Ondřej Fiala, Fernando Sabino Marques Monteiro, Alexandr Poprach et al. · 2024 · Targeted Oncology
94. Disproportionality analysis of drug-induced dry mouth using data from the United States food and drug administration adverse event reporting system database
    Dan Xu, Hong Zhu, Meng Chao Wu · 2024 · Heliyon
95. Biomarkers for evaluating the clinical response to immune checkpoint inhibitors in renal cell carcinoma (Review)
    Raquel González Garza, Adrián Gutiérrez‐González, Mario Cesar Salinas-Carmona, Manuel G. Mejia-Torres · 2024 · Oncology Reports
96. Gene expression of prostate-specific membrane antigen (FOLH1) in clear cell renal cell carcinoma predicts angiogenesis and response to tyrosine kinase inhibitors
    Sari Safaa Khaleel, Marlon Perera, Nathan P. Papa, Fengshen Kuo, Mahdi Golkaram, Phillip M. Rappold, Ritesh R. Kotecha, Jonathan Coleman, Paul Russo, Robert John Motzer et al. · 2024 · Urologic Oncology Seminars and Original Investigations
97. Immune Checkpoint Inhibition in Advanced Bladder and Kidney Cancer: Responses and Further Management
    Mamta Parikh, Thomas B. Powles · 2021 · American Society of Clinical Oncology Educational Book
98. First-line Immune Checkpoint Inhibitor Combinations in Metastatic Renal Cell Carcinoma: Where Are We Going, Where Have We Been?
    Jacob J. Adashek, Joshua J. Breunig, Edwin M. Posadas, Neil A. Bhowmick, Leigh Ellis, Stephen J. Freedland, Hyung Lae Kim, Robert A. Figlin, Jun Gong · 2022 · Drugs
99. A Pathological Complete Response to the Combination of Ipilimumab and Nivolumab in a Patient with Metastatic Renal Cell Carcinoma
    Hana Študentová, Anežka Zemánková, Martina Spisarová, Daniela Škanderová, Zbyněk Tüdös, Bohuslav Melichar, Vladimír Študent · 2022 · Medicina
100. Use of immunotherapy in clinical management of genitourinary cancers – a review
     Nataliya Mar, Edward Uchio, Arash Rezazadeh Kalebasty · 2022 · Cancer Treatment and Research Communications